CymaBay Therapeutics Company Profile (NASDAQ:CBAY)

About CymaBay Therapeutics

CymaBay Therapeutics logoCymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company's product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout. MBX-8025 is a selective agonist for the peroxisome proliferator-activated receptor delta (PPARd). The Company has completed over five Phase I clinical studies and a Phase II clinical study for MBX-8025. MBX-2982 is an oral, G-protein coupled receptor agonist being evaluated as a therapeutic agent for patients with Type 2 diabetes (T2DM), with a dual mechanism, including direct effects and indirect effects mediated by gastrointestinal hormones known as incretins on glucose-dependent insulin secretion, as well as potentially beneficial effects on islet health. The Company has completed over four Phase I clinical studies and a Phase II clinical study for MBX-2982.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CBAY
  • CUSIP:
Key Metrics:
  • Previous Close: $2.34
  • 50 Day Moving Average: $1.86
  • 200 Day Moving Average: $1.79
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.84
  • P/E Growth: 0.00
  • Market Cap: $56.27M
  • Outstanding Shares: 23,447,000
  • Beta: 0.72
Additional Links:
Companies Related to CymaBay Therapeutics:

Analyst Ratings

Consensus Ratings for CymaBay Therapeutics (NASDAQ:CBAY) (?)
Ratings Breakdown: 1 Hold Rating, 1 Buy Rating
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $2.25 (3.85% downside)

Analysts' Ratings History for CymaBay Therapeutics (NASDAQ:CBAY)
DateFirmActionRatingPrice TargetDetails
7/1/2016Roth CapitalInitiated CoverageBuyView Rating Details
6/1/2016HC WainwrightDowngradeBuy -> Neutral$6.00 -> $2.25View Rating Details
7/21/2015Piper Jaffray Cos.Initiated CoverageOverweight$4.00View Rating Details
5/8/2015Stifel NicolausReiterated RatingBuy$15.00 -> $9.00View Rating Details
(Data available from 8/24/2014 forward)


Earnings History for CymaBay Therapeutics (NASDAQ:CBAY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2016Q2($0.32)($0.30)ViewN/AView Earnings Details
5/12/2016Q1($0.28)($0.29)ViewListenView Earnings Details
3/29/2016Q4($0.35)($0.26)ViewListenView Earnings Details
11/12/2015Q315($0.33)($0.27)ViewListenView Earnings Details
8/10/2015Q215($0.42)($0.09)ViewListenView Earnings Details
5/7/2015($0.43)($0.44)ViewN/AView Earnings Details
3/18/2015Q414($0.47)($0.87)ViewN/AView Earnings Details
11/12/2014Q314($0.47)($0.44)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for CymaBay Therapeutics (NASDAQ:CBAY)
Current Year EPS Consensus Estimate: $-1.23 EPS
Next Year EPS Consensus Estimate: $-1.27 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.30)($0.30)($0.30)
Q3 20161($0.31)($0.31)($0.31)
Q4 20161($0.31)($0.31)($0.31)
Q1 20171($0.26)($0.26)($0.26)
Q2 20171($0.26)($0.26)($0.26)
Q3 20171($0.26)($0.26)($0.26)
Q4 20171($0.26)($0.26)($0.26)
(Data provided by Zacks Investment Research)


Dividend History for CymaBay Therapeutics (NASDAQ:CBAY)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for CymaBay Therapeutics (NASDAQ:CBAY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/15/2016Charles McwherterVPBuy3,000$1.68$5,040.00View SEC Filing  
4/5/2016Sujal ShahCFOBuy55,000$1.39$76,450.00View SEC Filing  
4/4/2016Sujal ShahCFOBuy22,000$1.39$30,580.00View SEC Filing  
9/11/2015Carl GoldfischerDirectorSell46,729$2.74$128,037.46View SEC Filing  
8/14/2015Emster Kurt VonDirectorBuy90,000$2.69$242,100.00View SEC Filing  
7/20/2015Emster Kurt VonDirectorBuy1,600,000$2.81$4,496,000.00View SEC Filing  
5/18/2015Sujal ShahCFOBuy10,000$3.40$34,000.00View SEC Filing  
5/18/2015Wart Harold VanCEOBuy7,500$3.34$25,050.00View SEC Filing  
5/15/2015Charles McwherterVPBuy2,000$3.16$6,320.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for CymaBay Therapeutics (NASDAQ:CBAY)
News IconCrowd & Analyst Ratings Update on Cymabay Therapeutics Inc. (NASDAQ:CBAY)? - Post News (NASDAQ:CBAY) - August 23 at 8:16 AM logoCymabay Therapeutics Inc. (NASDAQ:CBAY) Gets 0 Recommendations To Sell - Investor Newswire (NASDAQ:CBAY) - August 23 at 8:16 AM logoCYMABAY THERAPEUTICS, INC. Financials (NASDAQ:CBAY) - August 19 at 4:45 PM logoCYMABAY THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report (NASDAQ:CBAY) - August 18 at 8:45 PM
News IconCymabay Therapeutics, Inc.'s (CBAY): Stock to Track - Hot Stocks Point (NASDAQ:CBAY) - August 18 at 3:21 PM logoWill Cymabay Therapeutics Inc. (NASDAQ:CBAY) Hit $4 Price Target? - Investor Newswire (NASDAQ:CBAY) - August 15 at 9:42 PM logoWhats Hot Today: ProAssurance Corporation (NYSE:PRA), Cymabay Therapeutics, Inc. (NASDAQ:CBAY), AG&E ... - KC Register (NASDAQ:CBAY) - August 15 at 11:21 AM logoCymaBay Therapeutics' (CBAY) CEO Hal Van Wart on Q2 2016 ... - Seeking Alpha (NASDAQ:CBAY) - August 10 at 5:53 AM logoCymaBay Reports Second Quarter 2016 Financial Results (NASDAQ:CBAY) - August 9 at 5:10 PM logoCymaBay to Announce Second Quarter 2016 Financial Results on Tuesday, August 9 (NASDAQ:CBAY) - August 2 at 8:53 AM logoCan Shares Of Cymabay Therapeutics Inc. (NASDAQ:CBAY) Hit $4? - Investor Newswire (NASDAQ:CBAY) - July 26 at 9:16 AM
News IconIncreased Volatility Noted on Shares of: Cymabay Therapeutics, Inc. (NASDAQ:CBAY) - Engelwood Daily (NASDAQ:CBAY) - July 23 at 8:21 AM
News IconEquity Roundup: Stock Performance Focus on Cymabay Therapeutics Inc. (NASDAQ:CBAY) - Press Telegraph (NASDAQ:CBAY) - July 23 at 8:21 AM
News IconInsiders Increasing Positions in: Cymabay Therapeutics, Inc. (NASDAQ:CBAY) - Press Telegraph (NASDAQ:CBAY) - July 21 at 8:01 AM
News IconCymabay Therapeutics Inc. (NASDAQ:CBAY): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:CBAY) - July 20 at 11:24 PM
News IconCymabay Therapeutics Incorporated (NASDAQ:CBAY) Sellers Covered 10.84% of Their Shorts - Consumer Eagle (NASDAQ:CBAY) - July 20 at 11:24 PM logoIs $4 Price Target Attainable For Cymabay Therapeutics Inc. (NASDAQ:CBAY)? - Investor Newswire (NASDAQ:CBAY) - July 19 at 9:27 PM
News IconAre Analysts Bullish CymaBay Therapeutics Inc (NASDAQ:CBAY) After Last Week? - Consumer Eagle (NASDAQ:CBAY) - July 19 at 9:27 PM
News IconInvestor Watch: Volatility Recap on Shares of: Cymabay Therapeutics, Inc. (NASDAQ:CBAY) - Engelwood Daily (NASDAQ:CBAY) - July 18 at 4:17 PM
News IconStock Declining in Trading Session: Cymabay Therapeutics, Inc. (NASDAQ:CBAY) - TGP (NASDAQ:CBAY) - July 18 at 4:17 PM logoNext Weeks Broker Price Targets For Cymabay Therapeutics Inc. (CBAY) - Fiscal Standard (NASDAQ:CBAY) - July 17 at 3:53 PM
News IconEye on Stock Volatility for: Cymabay Therapeutics, Inc. (NASDAQ:CBAY) - Engelwood Daily (NASDAQ:CBAY) - July 15 at 1:51 PM
News IconSession Volatility Review for: Cymabay Therapeutics, Inc. (NASDAQ:CBAY) - Engelwood Daily (NASDAQ:CBAY) - July 13 at 4:07 PM logoCymabay Therapeutics Inc. (CBAY) Updated Price Targets - FTSE News (NASDAQ:CBAY) - July 13 at 4:07 PM logoBiotech Volatile Stocks: Cymabay Therapeutics, Inc. (NASDAQ:CBAY), MyoKardia, Inc. (NASDAQ:MYOK), Egalet ... - KC Register (NASDAQ:CBAY) - July 13 at 4:07 PM
News IconCymabay Therapeutics Inc. (NASDAQ:CBAY) Earnings Concentration and Analyst Target Watch - Engelwood Daily (NASDAQ:CBAY) - July 13 at 4:07 PM logoStrong Sell Calls For Cymabay Therapeutics Inc. (NASDAQ:CBAY) At 0 - Investor Newswire (NASDAQ:CBAY) - July 12 at 8:15 AM logoCymabay Therapeutics Inc. (CBAY) Broker Price Targets For The Coming Week - Fiscal Standard (NASDAQ:CBAY) - July 11 at 4:01 PM
News IconIncreased Volatility on Shares of: Cymabay Therapeutics, Inc. (NASDAQ:CBAY) - Engelwood Daily (NASDAQ:CBAY) - July 8 at 9:10 PM
News IconCan Cymabay Therapeutics Inc. (NASDAQ:CBAY) Improve on the Earnings Front? - Engelwood Daily (NASDAQ:CBAY) - July 8 at 4:07 PM
News IconHeightened Volatility Check on: Cymabay Therapeutics, Inc. (NASDAQ:CBAY) - Engelwood Daily (NASDAQ:CBAY) - July 8 at 4:07 PM logoCymaBay Announces Participation at Cantor Fitzgerald Healthcare Conference on July 12th in New York (NASDAQ:CBAY) - July 7 at 8:00 AM
News IconCovering the Bases on Cymabay Therapeutics Inc. (NASDAQ:CBAY): Where is the Stock Going? - Press Telegraph (NASDAQ:CBAY) - June 28 at 3:24 PM logoStrong Sell Calls Recommendations For Cymabay Therapeutics Inc. (NASDAQ:CBAY) At 0 - Investor Newswire (NASDAQ:CBAY) - June 28 at 8:56 AM
News IconCymabay Therapeutics Incorporated (NASDAQ:CBAY) Short Interest Increased By 23.92% - Engelwood Daily (NASDAQ:CBAY) - June 26 at 9:15 AM logoStrong Buy Calls Count For Cymabay Therapeutics Inc. (NASDAQ:CBAY) At 1 - Investor Newswire (NASDAQ:CBAY) - June 21 at 3:57 PM logoCYMABAY THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders (NASDAQ:CBAY) - June 6 at 4:33 PM logoBiolife (BLFS), Ardelyx (ARDX), Synchronoss (SNCR) are Big Moving Stocks Today (NASDAQ:CBAY) - June 6 at 9:03 AM logoAnalysts Rating Review: CymaBay Therapeutics Inc (NASDAQ:CBAY) - The Point Review (NASDAQ:CBAY) - June 2 at 10:08 PM logoMost Recent Stocks Movements: Cymabay Therapeutics Inc. (NASDAQ:CBAY) , Juno Therapeutics, Inc. (NASDAQ ... - Street Updates (NASDAQ:CBAY) - June 2 at 4:13 PM
News IconInsiders Are Gradually Buying Cymabay Therapeutics, Inc. (NASDAQ:CBAY) - HNN (NASDAQ:CBAY) - June 2 at 12:51 PM
News IconCymaBay Therapeutics Inc. (NASDAQ: CBAY)'s Buries Phase 2 Study Of MBX-8025, Now What? - Scibility Media (NASDAQ:CBAY) - June 2 at 12:51 PM logoTrader's Buzzer: Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), CymaBay Therapeutics Inc (NASDAQ:CBAY), Ampliphi ... - The Point Review (NASDAQ:CBAY) - June 1 at 10:12 PM logoCymaBay Therapeutics (CBAY) Ceases MBX-8025 Phase 2 in PBC Early After Primary Objective Met - (NASDAQ:CBAY) - June 1 at 4:10 PM logoSemGroup Corporation (NYSE:SEMG) Edged 7.76%: Cymabay Therapeutics, Inc. (NASDAQ:CBAY), Sprint ... - KC Register (NASDAQ:CBAY) - June 1 at 12:37 PM
News IconCymaBay Therapeutics Inc (CBAY) Lowered to Neutral at HC Wainwright - Let Me Know About This (NASDAQ:CBAY) - June 1 at 12:37 PM logoCymaBay Therapeutics downgraded by H.C. Wainwright (NASDAQ:CBAY) - June 1 at 7:08 AM
News IconShare Rating Focus on Cymabay Therapeutics Inc. (NASDAQ:CBAY) - HNN (NASDAQ:CBAY) - May 31 at 9:35 AM
News IconBroker Roundup For Cymabay Therapeutics Inc. (CBAY) - Share Trading News (NASDAQ:CBAY) - May 28 at 10:56 AM logoCYMABAY THERAPEUTICS, INC. : Regulation FD Disclosure (form 8-K) (NASDAQ:CBAY) - May 26 at 8:27 AM


CymaBay Therapeutics (NASDAQ:CBAY) Chart for Wednesday, August, 24, 2016

Last Updated on 8/24/2016 by Staff